Having trouble accessing articles? Reset your cache.

Brilinta ticagrelor: Additional Phase III data

Researchers from Uppsala University and colleagues reported data from a subgroup analysis of 10,285 patients who provided DNA samples for genetic analysis in the double-blind, double-dummy, international Phase III PLATO trial showing that Brilinta outperformed Plavix clopidogrel even in patients expected to respond well to Plavix because they lacked polymorphisms associated with

Read the full 526 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers